JAMA Internal Medicine
EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MARCH 9, 2020
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.0249?guestAccessKey=6b4c9980-58a8-4da3-b4ef-867607a4c2f2&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=030920
What The Study Did: This randomized clinical trial investigated if gabapentin, a drug often used to treat nerve pain, would be useful in the treatment of patients with alcohol use disorder (problem drinking that becomes severe) and a history of alcohol withdrawal symptoms. As many as 30 million people in the U.S. meet criteria for alcohol use disorder, yet less than 1 million receive medication that may be beneficial.
Authors: Raymond F. Anton, M.D., of the Medical University of South Carolina in Charleston, is the corresponding author.
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.